{"entity":{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","aka":[],"tldr":"A phase 3 trial testing JNJ-87189401 in prostate cancer, now recruiting.","summary":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT07164443, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3 Randomised, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 1203 participants (estimated). The study started in 2025-09-02 and primary completion is expected in 2028-08-18. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07164443","url":"https://clinicaltrials.gov/study/NCT07164443"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["jnj-87189401"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07164443","phase":"3","setting":"A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer","sponsor":"Janssen Research & Development","started":"2025-09-02","startedType":"actual","enrolled":1203,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/mcrpc/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}